Latest Breaking News On - Glenmarkspecialtysa - Page 1 : vimarsana.com

Glenmark receives acceptance from U.S. FDA for Phase 1/2, first-in-human clinical study of GRC 54276

Glenmark Specialty SA, has received acceptance from the U.S. FDA on its IND application for GRC 54276 to proceed with a Phase 1/2, first-in-human, clinical study of GRC 54276 for the treatment of patients with advanced solid tumors and lymphomas.